Voxelotor is designed to impeded the polymerization of sickle haemoglobin. Although FDA-
approved, its place in the treatment of sickle cell anaemia remains controversial. A report in …

Chimeric antigen receptor T (CAR-T) cells are a treatment option for patients with
relapse/refractory (R/R) non-Hodgkin lymphoma (NHL), acute lymphoid leukemia and …

In particular, diarrhoea occurred in 23% of patients receiving voxelotor 1500 mg in the
HOPE trial, more than double the frequency observed with placebo (11%). 19 Pro-active …

Objective Voxelotor, a FDA-approved drug for the treatment of patients with sickle cell
disease (SCD), inhibits hemoglobin S (HbS) polymerization and increases total hemoglobin …

Introduction The substitution of glutamic acid by valine on the ß-globin chain produces the
hemoglobin S variant responsible for sickle cell disease (SCD), a disorder that affects …

Sickle cell disease (SCD) is one of the most common inherited blood disorders.
Deoxygenated hemoglobin S (HbS) polymerizes and causes anemia and various end organ …

Background Sickle cell disease is an inherited disorder characterized by the presence of
sickle hemoglobin (HbS). The process of Hb molecule polymerization is a pivotal step in the …

Pain is a common complication of sickle cell disease. Sickle cell pain can often be effectively
managed by pediatricians in outpatient and hospital settings. Acute pain management …

Sickle cell disease refers to a group of inherited blood disorders in which hemoglobin
polymerization leads to hemolysis and vaso-occlusion. This causes a myriad of …